HDAC inhibitors in HIV. (Q37956178)

25 August 2017

HDAC inhibitors in HIV. (English)

1 reference

25 August 2017

0 references

4

1 reference

25 August 2017

Fiona Wightman

1

0 references

author name string

Paula Ellenberg

series ordinal

2

1 reference

PubMed ID

22083528

25 August 2017

Melissa Churchill

series ordinal

3

1 reference

25 August 2017

15 November 2011

1 reference

Immunology & Cell Biology

25 August 2017

1 reference

25 August 2017

90

1 reference

25 August 2017

1

1 reference

25 August 2017

47-54

1 reference

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

25 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Not all CD4+ memory T cells are long lived

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Chromatin dynamics associated with HIV-1 Tat-activated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Determinants of the establishment of human immunodeficiency virus type 1 latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Regulation of HIV-1 latency by T-cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

HIV reservoirs and latency models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

HIV integration site distributions in resting and activated CD4+ T cells infected in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

An in vitro system to model the establishment and reactivation of HIV-1 latency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Combinatorial latency reactivation for HIV-1 subtypes and variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Primary cell model for activation-inducible human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Histone acetyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Activation of latent HIV using drug-loaded nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Epigenetic regulation in myelodysplastic syndromes: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Cell line-dependent variability in HIV activation employing DNMT inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Glial cell-specific regulation of the JC virus early promoter by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

7 January 2021

Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

7 January 2021

Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

7 January 2021

Induction of chromosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

7 January 2021

No change to HIV-1 latency with valproate therapy

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

7 January 2021

Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

7 January 2021

A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.95

7 January 2021

Identifiers

DOI

10.1038/ICB.2011.95

1 reference

25 August 2017

1 reference

PubMed ID

22083528